• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Epic Sciences completes $13M Series B financing to advance cancer diagnostics

Epic Sciences completes $13M Series B financing to advance cancer diagnostics

November 14, 2012
CenterWatch Staff

Epic Sciences, a La Jolla, Calif.-based private biotech company that develops breakthrough cancer diagnostics, completed a $13 million Series B equity financing. This financing includes new investors Domain Associates, Roche Venture Fund and Pfizer Venture Investments, in addition to undisclosed individual investors.

Epic is developing highly sensitive diagnostic tests that molecularly characterize circulating tumor cells (CTCs) in the blood to provide a better way to detect cancer and to monitor and personalize cancer treatments. CTCs are cells that escape from solid tumors, enter the bloodstream where they travel and eventually cause cancer metastasis. Today, solid cancers are first detected by invasive biopsies, which cannot be used repeatedly and are ineffective in understanding metastatic risk, disease progression and treatment effectiveness. A blood test that can accurately detect and profile biomarkers on CTCs can be conducted repeatedly and can give essential, real-time information about disease status to tailor treatments to a patient's specific tumor.

"Epic's technology has achieved an unprecedented level of sensitivity in detecting circulating tumor cells to develop crucial cancer diagnostics for the millions of patients who need to understand whether their treatment is working and the status of their disease," said Dr. Kamdar, partner at Domain Associates, and newly appointed member of Epic’s board of directors. "With deep vertical integration of expertise in engineering, computation, pathology and oncology, we see that Epic's technology will not only have a major impact on clinical cancer treatments but also on the development of new cancer therapeutics and companion diagnostics."

With the proceeds from the financing, Epic will expand R&D operations and capabilities to commercialize the company's CTC platform, the basis of which has been exclusively licensed from Dr. Peter Kuhn's laboratory at The Scripps Research Institute. Epic is currently working with seven pharmaceutical partners to create companion diagnostic products for oncology drug candidates. The partnerships include a number of phase I and II clinical trials ultimately involving more than 1,500 patients. With these collaborations, Epic is developing a strong and diverse pipeline of companion diagnostic products.

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing